Clinical Trials
8 trialsNCT03532295 2025-11-21
Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
Washington University School of Medicine
Phase 2 Completed
NCT03322540 2025-08-22
Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)
Incyte Corporation
Phase 2 Completed
NCT03006302 2024-10-08
Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03602586 2024-07-26
Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT03196232 2024-01-23
Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer
Stanford University
Phase 2 Completed
NCT03322566 2022-01-24
A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)
Incyte Corporation
Phase 2 Completed
NCT01961115 2018-06-08
Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT01822691 2016-01-18
Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed